Palvella Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Palvella Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $215.75M.
- Palvella Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $265.00K.
- Palvella Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $9.67M.
- Palvella Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-12-31 was $0.00.
- Palvella Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $19.68M, a 187.65% increase from fiscal 2022.
- Palvella Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $6.84M.
- Palvella Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $9.62M, a 68.95% decline from fiscal 2019.
- Palvella Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2019 was $31.00M, a 34.34% decline from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $215.75M 10-Q · filed 2026-08-04 | |
| 2023-12-31 | $19.68M 10-K · filed 2024-03-29 | |
| 2022-12-31 | $6.84M 10-K · filed 2023-03-31 | |
| 2022-09-30 | $265.00K 10-Q · filed 2022-11-04 | |
| 2021-03-31 | $9.67M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $9.62M 10-K · filed 2021-03-31 |
| 2020-09-30 | $9.62M 10-Q · filed 2020-11-04 | |
| 2019-12-31 | $31.00M 10-K · filed 2021-03-31 | |
| 2018-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $47.21M 10-K · filed 2020-03-13 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | |
| 2018-03-31 | $47.21M 10-Q · filed 2019-05-10 | |
| 2016-12-31 | $15.22M 10-K · filed 2018-03-15 | |
| 2015-12-31 | $25.76M 10-K · filed 2017-03-30 | |
| 2014-12-31 | $11.96M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |